Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.5 USD | -1.45% | -6.48% | +83.82% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.66B |
---|---|---|---|---|---|
Net income 2024 * | -266M | Net income 2025 * | -277M | EV / Sales 2024 * | - |
Net Debt 2024 * | 10.59M | Net cash position 2025 * | 190M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.13
x | P/E ratio 2025 * |
-6.69
x | Employees | 328 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.37% |
Latest transcript on Sana Biotechnology, Inc.
1 day | -1.45% | ||
1 week | -6.48% | ||
1 month | -23.31% | ||
3 months | -33.45% | ||
6 months | +85.64% | ||
Current year | +83.82% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Harr
FOU | Founder | 53 | 18-07-12 |
Nathan Hardy
DFI | Director of Finance/CFO | 48 | 18-08-31 |
Gary Meininger
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 20-04-30 | |
Patrick Yang
BRD | Director/Board Member | 75 | 18-09-30 |
Robert Nelsen
FOU | Founder | 60 | 18-07-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 2 M€ | -.--% | ||
0.05% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 1,487 M€ | +7.77% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 7.5 | -1.45% | 2,569,190 |
24-05-30 | 7.61 | -1.81% | 1,367,060 |
24-05-29 | 7.75 | -0.64% | 1,169,671 |
24-05-28 | 7.8 | -2.74% | 1,153,071 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+83.82% | 1.66B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- SANA Stock